EAN 2023: Atogepant Effectively Reduces Monthly Migraine Days, Improves Quality of Life
Data from the ELEVATE trial show improvement in quality of life with atogepant versus placebo maintained through week 12
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.